45.59
-0.67 (-1.45%)
| Penutupan Terdahulu | 46.26 |
| Buka | 46.39 |
| Jumlah Dagangan | 433,428 |
| Purata Dagangan (3B) | 860,445 |
| Modal Pasaran | 2,614,100,992 |
| Harga / Pendapatan (P/E Ke hadapan) | 20.16 |
| Harga / Jualan (P/S) | 3.76 |
| Harga / Buku (P/B) | 2.49 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | 9.27% |
| Margin Operasi (TTM) | -4.67% |
| EPS Cair (TTM) | 1.11 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 4.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 1,204.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.13% |
| Nisbah Semasa (MRQ) | 2.44 |
| Aliran Tunai Operasi (OCF TTM) | 164.15 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 138.80 M |
| Pulangan Atas Aset (ROA TTM) | 2.76% |
| Pulangan Atas Ekuiti (ROE TTM) | 6.32% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menaik | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Bercampur | |
| Stok | Supernus Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.50 |
|
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 4.11% |
| % Dimiliki oleh Institusi | 109.15% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 65.00 (B of A Securities, 42.58%) | Beli |
| 65.00 (Piper Sandler, 42.58%) | Beli | |
| Median | 64.00 (40.38%) | |
| Rendah | 60.00 (TD Cowen, 31.61%) | Beli |
| Purata | 63.25 (38.74%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 51.25 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| B of A Securities | 29 Oct 2025 | 65.00 (42.58%) | Beli | 55.68 |
| TD Cowen | 23 Oct 2025 | 60.00 (31.61%) | Beli | 52.02 |
| Piper Sandler | 09 Oct 2025 | 65.00 (42.58%) | Beli | 49.51 |
| Cantor Fitzgerald | 30 Sep 2025 | 63.00 (38.19%) | Beli | 47.79 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| NEWHALL CHARLES W III | - | - | 0 | 0 |
| Jumlah Keseluruhan Kuantiti Bersih | 0 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 0 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| NEWHALL CHARLES W III | Pengarah | 21 Nov 2025 | Pelaksanaan pilihan | 15,000 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 21 Nov 2025 | Pengumuman | Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference |
| 12 Nov 2025 | Pengumuman | Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London |
| 04 Nov 2025 | Pengumuman | Supernus Announces Third Quarter 2025 Financial Results |
| 21 Oct 2025 | Pengumuman | Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |